Clinical Trials Browser

Phase 2/3 × Temozolomide × Endocrine × Clear all

NCT04244708 2020-01-28

The Effect of Chemoradiotherapy in Patients With Refractory Pituitary Adenomas

Phase 2/3 Unknown

Pituitary Neoplasms